XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
Search

Last Updated: Nov 18, 2006 - 1:55:25 PM

Renal Cell Carcinoma Channel
subscribe to Renal Cell Carcinoma newsletter

Latest Research : Cancer : Renal Cell Carcinoma

   DISCUSS   |   EMAIL   |   PRINT
Bayer wins positive response for cancer drug
Apr 30, 2006 - 7:25:00 PM, Reviewed by: Dr. Priya Saxena

A positive ruling by the commission could pave the way for a marketing authorisation for all EU nations in the second half of this year.

 
Bayer AG said Friday that the company and its US partner Onyx Pharmaceuticals Inc have received a positive response from European officials to their drug to treat kidney cancer.

The opinion of the European Committee for Medicinal Products for Human Use (CHMP) of the drug Nexavar would now be passed onto the European Commission.

A positive ruling by the commission could pave the way for a marketing authorisation for all EU nations in the second half of this year.

The announcement coincided with Bayer's annual general meeting in Cologne, where the group's chief Werner Wenning sought to secure shareholders' support for the planned 16.5 billion euros ($21 billion) takeover of rival pharmaceuticals firm Schering AG.

Describing the proposed acquisition as a milestone in the company's history, Wenning said that this move was the "right step" for the group.

The takeover, Wenning said, would propel Bayer into "the top league of pharmaceutical makers around the world".

Wenning went on to tell the company's shareholders that the acquisition would result in the health services section emerging as the key engine for growth.

Bayer's 86-euro a share offer for Berlin based Schering runs until the end of May with the takeover representing the biggest acquisition in Bayer's corporate history.
 

- Indo-Asian News Service
 

 
Subscribe to Renal Cell Carcinoma Newsletter
E-mail Address:

 



Related Renal Cell Carcinoma News
Tailor made approach to kidney cancer
Temsirolimus is effective for advanced renal cell carcinoma
Renal cancer related to deficiency in exposure to sunlight
Sunitinib malate more effective than standard cytokine treatment in metastatic renal cell carcinoma (mRCC)
Bayer wins positive response for cancer drug
Imatinib mesylate is not likely to be effective for patients with high grade renal cell carcinoma


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us